GenSight Biologics S.A. (EPA:SIGHT)
0.0995
-0.0005 (-0.50%)
Jan 9, 2026, 5:35 PM CET
GenSight Biologics Employees
GenSight Biologics had 16 employees as of December 31, 2024. The number of employees did not change compared to the previous year.
Employees
16
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
€72,692
Profits / Employee
€1,163,077
Market Cap
21.94M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 16 | 0 | - |
| Dec 31, 2023 | 16 | -29 | -64.44% |
| Dec 31, 2022 | 45 | 7 | 18.42% |
| Dec 31, 2021 | 38 | 13 | 52.00% |
| Dec 31, 2020 | 25 | 0 | - |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| EssilorLuxottica Société anonyme | 153,498 |
| emeis Société anonyme | 83,494 |
| Sanofi | 82,878 |
| Eurofins Scientific SE | 62,696 |
| Clariane SE | 61,798 |
| Ramsay Générale de Santé | 40,494 |
| bioMérieux | 14,754 |
| Sartorius Stedim Biotech | 9,901 |
GenSight Biologics News
- 1 day ago - GenSight Biologics Reports Cash Position as of December 31, 2025, and Provides Business Updates - Business Wire
- 2 days ago - GenSight Biologics Announces Closing of Fundraising Worth Nearly EUR 2.9 Million • news - Onvista
- 18 days ago - GenSight Biologics Announces Regulatory Authorization for Early Access Treatment with GS010/LUMEVOQ® in Israel - Business Wire
- 19 days ago - GenSight Biologics Announces the Granting of Compassionate Use Authorization (CUA/AAC) for GS010/LUMEVOQ® in France - Business Wire
- 5 weeks ago - GenSight Biologics Announces Regulatory Approval for GS010/LUMEVOQ® REVISE Dose-Ranging Study in France - Business Wire
- 2 months ago - GenSight Biologics Announces Closing of Fundraising Worth Nearly EUR 2 Million • news - Onvista
- 2 months ago - GenSight Biologics Announces Regulatory Authorizations for Individual Patient Expanded Access Treatment with GS010/LUMEVOQ® in the US - Business Wire
- 3 months ago - GenSight Biologics Reports Cash Position as of September 30, 2025 - Business Wire